Advances in Vaccine Technology
Human papillomaviruses (HPVs) are the causative agent for recurrent respiratory papillomatosis, cancer of the cervix, and squamous cell carcinoma of the head and neck. Vaccines are available to prevent infection with several of the HPV types that are responsible for causing these serious diseases. This chapter discusses the development, successes, and limitations of these prophylactic L1-based vaccines. Potential for L2-based vaccines to provide broad coverage to prevent infection with many HPV types is also discussed. Finally, research into treatment of established HPV infection and resultant disease using therapeutic vaccines is outlined.
KeywordsHuman papillomavirus Vaccine Gardasil Cervarix Recurrent respiratory papillomatosis
- (CDC) CfDCaP. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591–5.Google Scholar
- Bayas JM, Costas L, Munoz A. Gynecol Oncol. Cervical cancer vaccination indications, efficacy, and side effects. 2008;110(3 Suppl 2):S11–4.Google Scholar
- Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.CrossRefPubMedPubMedCentralGoogle Scholar
- Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004–2008. Morbidity Mortality Weekly Rep. 2012;61(15):258–61.Google Scholar
- Markowitz LE, Dunne EF, Saraiya M, Lawson HW, et al. Quadrivalent human papilloma vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;23(56(RR-2):1–24.Google Scholar
- Nygård M, Krüger Kjaer S, Dillner J, et al. Long-term effectiveness and immunogenicity of Gardasil™ in the Nordic countries. In: Poster presented at Eurogin 2013: HPV at a Crossroads – 30 Years of Research and Practice; 3–6 Nov 2013. Florence, Italy.Google Scholar
- Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–86.CrossRefPubMedPubMedCentralGoogle Scholar
- State Vaccination Requirements. 29 Jan 2016. Retrieved July 19, 2016, from http://www.cdc.gov/vaccines/imz-managers/laws/state-reqs.html.
- Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.CrossRefPubMedPubMedCentralGoogle Scholar
- Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy for treatment of recurrent respiratory papilloma. J Voice 2015; 229:223–229.Google Scholar